1st Day of Advent...

Wishing all our wonderful supporters a fabulous Christmas!

Listen to our late President and Co-founder Tom Isaacs' rendition of 'The First Day of Christmas...'

The_First_Day_of_Xmas.mp3

See our Christmas advent here.

Latest

The Behaviours of Alpha-Synuclein

Researchers are beginning to better understand the behaviours of the alpha-synuclein protein implicated in Parkinson's. In this article, Linked Clinical Trials committee member David Sulzer discusses the findings...
Could Changes in the Levels of Serotonin Signal Parkinson's?

Researchers from King's College London have uncovered the earliest signs of Parkinson's in the brain, long before any symptoms are evident. The results could potentially lead to screening tools for identifying people at greatest risk - an important area of research interest...
CuATSM - A Promising Compound

Following on from interesting results in a clinical trial of motor neurone disease earlier this year this new study in Parkinson's further supports the potential utility of this compound...
The Ridgway Mini-Fest

Join supporter and long time friend of The Cure Parkinson’s Trust Barbara Thompson for a fantastic afternoon of music and food at The Ridgway Mini-Fest on Saturday 27th July.

24th Day of Advent - It's Christmaaaasss!

Well... what an inspiring year! A huge and heartfelt thank you to everyone for being part of it...
23rd Day of Advent

Looking back over the year, we’ve showcased a few more fantastic fundraising events taken on by our wonderful individual fundraisers...
22nd Day of Advent

Scientists at the MRC Centre for Regenerative Medicine (University of Edinburgh)- led by Dr Tilo Kunath and part-funded by The Cure Parkinson's Trust (CPT) - have published a research report demonstrating that genetically reducing alpha synuclein, using gene editing, results in a measure of resistance to one of the pathological hallmarks of Parkinson's.
21st Day of Advent

In November we reported on a team of investigators who had blocked neuron death by treating the affected neurons with a repurposed medicine already available in the form of 'PARP1 inhibitors'. In models of Parkinson's, this treatment not only reduced levels of alpha synuclein, but also prevented the loss of dopamine neurons.
20th Day of Advent

This year CPT was delighted to be the beneficiary charity of both the 30th Anniversary Gulls' Eggs and the Grouse & Grape Luncheons.
19th Day of Advent

CPT in association with Bonhams and Artwise were thrilled to be part of the second edition of Cure3 in October, an acclaimed selling exhibition devised to raise awareness and funds for Parkinson’s research.
18th Day of Advent

In September we announced the winners of the Tom Isaacs Award...
17th Day of Advent

In September, our Linked Clinical Trials committee met for the sixth year running - a pioneering collaborative meeting of many of the world's leading Parkinson's authorities, to discuss fast tracking potential drugs for repurposing in Parkinson's ...
16th Day of Advent

This year we have seen so many amazing individuals set themselves inspiring running challenges in support of CPT including…
15th Day of Advent

In August, CPT was delighted to announce that the R S MacDonald Charitable Trust awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath in Edinburgh...

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed drugs

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Alpha-synuclein and Parkinson's

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Our Annual Review 2019

Our Annual Review 2019 - your online publication here... Read more

Parkinson's Movement

The Science of Parkinson's - Dr Simon Stott

Leave a gift in your Will

A donation to The Cure Parkinson's Trust will make a huge difference to our research to slow, stop or even reverse Parkinson's. Read more